Table 2.
Baseline characteristics of the enrolled cohort
| Enrolled cohort (n = 336) | Valuea |
|---|---|
| Age | 61.9 (9.0) |
| Male gender, n (%) | 230 (68.5) |
| White, non‐Hispanic, n (%) | 300 (89.3) |
| Years from diagnosis | 0.9 (0.7) |
| Hoehn and Yahr Stage | 1.7 (0.5) |
| Schwab and England ADL score | 94.0 (7.9) |
| Total UPDRS | 23.1 (8.6) |
| Mental UPDRS | 0.7 (1.1) |
| ADL UPDRS | 5.2 (3.1) |
| Motor UPDRS | 17.2 (7.0) |
| MDS‐UPDRS Total | 32.4 (11.6) |
| MoCA | 28.1 (1.4) |
| Amantadine use at baseline, n (%) | 20 (6.0) |
| Anticholinergic use at baseline, n (%) | 5 (1.5) |
ADL, activities of daily living; UPDRS, Unified Parkinson Disease Rating Scale; MDS, Movement Disorders Society; MoCA, Montreal Cognitive Assessment.
a
Values represent mean (standard deviation) unless otherwise specified.